Last updated on August 2018

A Study Evaluating ABI-H0731 as Adjunctive Therapy in HBeAg-positive Patients With Chronic Hepatitis B


Brief description of study

The purpose of this study is to determine if ABI-H0731 given in combination with a standard of care HBV medication is safe and effective in patients with chronic hepatitis B.

Detailed Study Description

This is a Phase 2a, Multi-center, Double-blind, Placebo-controlled Study Evaluating ABI-H0731 as Adjunctive Therapy in Virally-suppressed HBeAg-positive Patients with Chronic Hepatitis B

Clinical Study Identifier: NCT03576066

Contact Investigators or Research Sites near you

Start Over

Assembly Biosciences

NYU Langone Health
New York, NY United States
2.62miles
  Connect »

Assembly Biosciences

Icahn School of Medicine at Mount Sinai
New York, NY United States
6.33miles
  Connect »